lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The editor-in-chief of the Journal of Clinical Oncology shares the results of our phase 3 study. $nwbo #dcvax
— Ida Bogac (@albtur_mnymkrs) November 23, 2022
I would expect nothing less, #dcvax soon to be SOC? $nwbo https://t.co/RVeuWPQo2C
When the music's over turn off the light
Nature could have published DCVax. Should we expect Lancet to endorse our trial next? It seems the only detractors are those upset they don't own 1M shares.
AZ isn't getting NWBO but we love the jealousy ;)
Yes, it doesn't matter what traders are doing with NWBO OTC stock.
The arbiters of science with deep pockets love DCVax.
Tides they are turning
Congrats from a Chief Scientist, Cancer Immunology at AstraZeneca to the CTO of $NWBO - seems pretty significant to me! #DCVax #murcidencel
— Profit Sharing through Investing (@PlaysForTheDay) November 23, 2022
(Per a screenshot posted by Dubody on StockTwits- looks credible!) pic.twitter.com/OMwx6JNN7X
Shorts coming out of the woodwork like termites suffering fumigation.
Certainly he does not. About to lose his Valeant money shorting NWBO!
Shareholders at Merck and BMY really hate adding billions in revenue.
50% cure rate and rising.
Yes, Les Goldman's going to let Linda Powers dilute his shares. Les has no interest in Advent or Toucan. Same for the Board. The idea that we have some insane CEO screwing everyone else with a large vested interest makes no sense.
Management have lost around 100M in paper money over the last few days due to OTC swing traders.
Do you think they're happy with that result?
They would only tolerate it if a much larger payoff was coming.
Can you cite another company that defeated GBM using a platform applicable to all solid tumors? Comps don't exist because this has never been done before.
Why would management sell a $100B company for $15B?
Do you think management with their approximately 300M shares want to leave nearly $20B in cash on the table?
They're not Elon Musk simply willing to light their own money on fire.
I agree Nature = huge and a competing journal in some respects.
You too! Think of the Glioblastoma patients and how much better they will be once DCVax reaches the market.
There's not enough investors on OTC for the price to have any genuine reflection of the results presented in JAMA. After being on a road trip for 20 hours, I was quite despondent with what began yesterday. Though my expectations were not realistic at this stage. We are going to see a significant disconnect as long as we remain on OTC.
Do we have a list of companies which defeated Glioblastoma with an oncology platform applicable to all solid tumors?
I didn't interrogate Dave. It really doesn't matter to me at this point.
BP dividends increase through revolutionary platforms like DCVax. Of course they will pay more than $20 a share.
When BMY and MRK compete for DCVax NWBO wins.
"We have confidentiality agreements with all of our consultants." - DI
If one BP won't pay another will. This is a zero sum game. The company that doesn't own DCVax will lose extensive market share.
Well said! Thank you!
Squeeze of that magnitude would bankrupt even the likes of Stevie Cohen.
BP has had the data since NYAS. They don't need to market DCVax to potential buyers when buyers have the prerequisite information already. Doing so can make current buyers think management are shopping around. If management start doing that then this could tell us they want a higher price.
Buyout price determined by revenue created with DCVax not shallowness of OTC order book!
It would be criminal negligence for a doctor to not use DCVax once it becomes standard of care. They do not guarantee outcomes but they must meet the standard of skill established in the profession. JAMA, imminent approval, and then clinical practice guidelines will make that the case as well as an insurable price through our innovative manufacturing process.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088386/
The fact they have no staff suggests some collaboration with an entity that does, though as ATL points out when DCVax becomes SOC for GBM doctors will be required to prescribe it to patients. They do not need a sales team to market the drug as JAMA does that for free. So I can see them being able to remain independent for the short term if they don't get a deal on terms they find advantageous. What the structure of that deal looks like? I trust management who are much older and wiser than I am to make that determination.
Order a pallet. We can sell it to Novocure shareholders after the news comes out.
I benefit from the wisdom of crowds.
Don't get ahead of yourself. We still have the entire month of December.
Management never told me they planned a short trap. Their strategy may have changed. If somebody has their checkbook open it makes sense to not pump the stock as that could be seen as a hostile act to take during negotiations. Similarly I don't see a buyer trying to drive down the price of our stock either. LP will have multiple interested parties. The price fluctuations are traders who don't care about what management are doing rather they act on short term signals.
Dave will not speak to me. I messaged him about uplisting strategy last Friday. He only said:
"Would you just enjoy the day for now."
If they don't seem to care about promoting their results it's probably because the key players already know everything.
If there wasn't a deal pending the firm would be trying to raise the stock price so they can uplist. Given they don't seem to care says all we should need to know.
Management owns around 300M shares yet don't seem concerned about the stock price. If indeed their UK PR agency was let go, while we don't see much US press, then that could indicate a deal nears. Let's not forget all of the short term note extension agreements, either.
Most market makers are working 24/7 with exception of NYSE holidays. These will fulfill institutional orders. I don't think Thanksgiving has any impact on Landmark Trial Data during a bear market when everyone's looking for a stock that runs counter to the market.
Celebrating with family who are buying more this week.
We allocated billions to onshore semiconductor production. Why not the same to be the world leader in immunotherapy manufacturing?
Not intervene but showcase the leadership present in his FDA as well as raise awareness for GBM patients.